US Stock MarketDetailed Quotes
MNST Monster Beverage
- 49.740
- -1.860-3.60%
Close Jan 10 16:00 ET
- 49.600
- -0.140-0.28%
Post 20:01 ET
48.37BMarket Cap31.88P/E (TTM)
51.405High49.680Low6.71MVolume51.240Open51.600Pre Close335.56MTurnover0.97%Turnover Ratio32.30P/E (Static)972.52MShares61.22552wk High8.37P/B34.35BFloat Cap43.32052wk Low--Dividend TTM690.51MShs Float61.225Historical High--Div YieldTTM3.34%Amplitude0.010Historical Low50.036Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Monster Beverage Stock Forum
Always have a trading plan. Set clear goals. Define your risk tolerance and outline your entry and exit strategies before placing any trad
So, here’s the deal: Monster thought they were the king of the energy drinks, but they only brought in $1.9 billion in Q2. Now, $1.9 billion sounds like a big ol' chunk of change, right? But the analysts—those cheeky buggers—were expecting $2.01 billio...
Eli Lilly $Eli Lilly and Co (LLY.US)$ posted a Q2 earnings beat, boosted by demand for the company's Mounjaro diabetes treatment and weight-loss drug Zepbound. The stock climbed 8%, and ...
consumers are not spending we are not consuming at the rate that we used to
Gapping up
$Eli Lilly and Co (LLY.US)$ 's stock increased by 11.5% after the pharmaceutical company boosted its annual profit forecast, with sales of its weight-loss drug Zepbound surpassing the $1 billion mark in a single quarter for the first time.
$Apple (AAPL.US)$ 's stock edged up by 0.1% following a report from CNBC that the tech giant may introduce a charge of up to $20 for advanced artificial intelligence f...
MNST fell 9% to $46 shortly before 4:45 p.m. ET after reporting $1.9 billion of Q2 net sales, rising from $1.85 billion in the same period last year, but missing the $2.01 billion consensus that analysts had reportedly expected.
Diluted earnings per share came in at...
As of July 31, the Nasdaq Index has fallen 5.7% after hitting a record high of 18,671 points on July 11. Meanwhile, the S&P 500 Consumer Select Sector Index remained nearly flat, the S&P Biotechnology Select Industry Index rose 3.7%, and the $Russell 2000 Index (.RUT.US)$ gained 10.7...
No comment yet